Nestle Health Science, a subsidiary of Nestle, has increased its share in Aimmune Therapeutics, a biopharmaceutical company involved in the development of advanced treatments for life-threatening food allergies, by making an additional equity investment of USD98m, it was reported yesterday.

The latest investment brings Nestle's total investment in the drug developer for food allergies to USD273m. The equity investment is likely to be completed by the end of 2018, subject to customary closing conditions.

Both companies have also signed a two-year extension of their original two-year strategic collaboration deal, which is involved in offering advanced food allergy therapies. The deal is said to not contain any partnership, collaboration, or negotiation restrictions on Aimmune. Aimmune holds all rights to its present and future pipeline assets, while Aimmune and Nestle Health Science will collaborate on development of such assets.